Auvelity as a Potential Treatment for Alzheimer’s Disease
Open accessAbstract
Alzheimer’s disease is the most common form of dementia affecting older adults. Alzheimer’s disease also shares a significant association with Major Depressive Disorder. Glutamatergic excitotoxicity via NMDA receptors is believed to be a key mechanism underlying neurodegeneration in Alzheimer’s Disease. Blockade of NMDA receptors by NMDA antagonists like Memantine appears to inhibit glutamatergic excitotoxicity. Memantine also increases dopaminergic activation through agonism of sigma-1 receptors. The combination of these two mechanisms is believed to underlie Memantine’s improvements in memory, cognition and general functioning in AD patients. Auvelity was recently approved by the FDA for the treatment of Major Depressive Disorder in adults. Auvelity’s relevant mechanism of action is a combination of its blockade of NMDA receptors with consequent antagonism of the glutamatergic neurotransmitter pathway, and its agonism of the sigma-1 receptor. Because Auvelity and AD medications like Memantine employ the same mechanism of action, it is hypothesized that Auvelity might be a potential medical treatment for reducing the symptoms of Alzheimer’s disease.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Auvelity has received a fast-track designation from the FDA to treat Alzheimer's disease.
“Auvelity has also received a fast-track designation from the FDA to treat Alzheimer's disease”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [188]
The 'Auvelity: A Novel Antidepressant' section reports FDA approval for major depressive disorder, while the Discussion and Conclusion describes treatment of Alzheimer’s disease as hypothetical. Neither section reports an FDA fast-track designation for Alzheimer’s disease; the absence of approval for that indication does not settle whether a fast-track designation was granted. Searches for 'fast-track designation' and 'fast track FDA designation' found no passage addressing it. (LLM, conf=0.75)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Ownby, R. L., Crocco, E., Acevedo, A., John, V., & Loewenstein, D. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.5.530 · Cited by 1,493 · see citing works
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155 · see citing works
Role of Glutamate and NMDA Receptors in Alzheimer’s Disease
Wang, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160763 · Cited by 1,009 · see citing works
Glutamate as a neurotransmitter in the healthy brain
Zhou, Y., & Danbolt, N. C. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1180-8 · Cited by 989 · see citing works
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond
Lipton, S. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1958 · Cited by 909 · see citing works
Overview of depression and psychosis in Alzheimer's disease
Wragg, R. E., & Jeste, D. V. (1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.5.577 · Cited by 683 · see citing works
Structure, function, and allosteric modulation of NMDA receptors
Hansen, K. B., Yi, F., Perszyk, R. E., Furukawa, H., Wollmuth, L. P., Gibb, A. J., & Traynelis, S. F. (2018) · The Journal of General Physiology · doi:10.1085/jgp.201812032 · Cited by 574 · see citing works
The Role of NMDA Receptors in Alzheimer’s Disease
Liu, J., Chang, L., Song, Y., Li, H., & Wu, Y. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00043 · Cited by 535 · see citing works
Mechanism of action of memantine
Johnson, J. M., & Kotermanski, S. E. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.09.007 · Cited by 500 · see citing works
The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's Disease
Rogawski, M. A., & Wenk, G. L. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00254.x · Cited by 438 · see citing works
Mechanisms of Glutamate Transport
Vandenberg, R. J., & Ryan, R. M. (2013) · Physiological Reviews · doi:10.1152/physrev.00007.2013 · Cited by 349 · see citing works
The Role of Monoamine Metabolism in Oxidative Glutamate Toxicity
Maher, P. A., & Davis, J. B. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-20-06394.1996 · Cited by 338 · see citing works
Correlation between plasma levels of glutamate, alanine and serine with severity of depression
Mitani, H., Shirayama, Y., Yamada, T., Maeda, K., Ashby, C. R., & Kawahara, R. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.03.036 · Cited by 332 · see citing works
McShane, R., Westby, M. J., Roberts, E., Minakaran, N., Schneider, L., Farrimond, L. E., Maayan, N., Ware, J., & Debarros, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub6 · Cited by 310 · see citing works
Lack of Evidence for the Efficacy of Memantine in Mild Alzheimer Disease
Schneider, L. S. S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.69 · Cited by 276 · see citing works
Mathews, D. C., Henter, I. D., & Zarate, C. A. (2012) · Drugs · doi:10.2165/11633130-000000000-00000 · Cited by 220 · see citing works
Ali, T. B., Schleret, T. R., Reilly, B. M., Chen, W. Y., & Abagyan, R. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144337 · Cited by 182 · see citing works
Haake, A., Nguyen, K. T., Friedman, L. G., Chakkamparambil, B., & Grossberg, G. T. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1721456 · Cited by 182 · see citing works
Alzheimer’s disease: Targeting the glutamatergic system
Conway, M. E. (2020) · Biogerontology · doi:10.1007/s10522-020-09860-4 · Cited by 180 · see citing works
Diagnosing and Treating Depression in Patients with Alzheimer’s Disease
Burke, A. D., Goldfarb, D., Bollam, P., & Khokher, S. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-00148-5 · Cited by 115 · see citing works
Involvement of the sigma1 receptor in the modulation of dopaminergic transmission by amantadine
Peeters, M., Romieu, P., Maurice, T., Su, T., Maloteaux, J., & Hermans, E. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03297.x · Cited by 107 · see citing works
Delusions and hallucinations in dementia with Lewy bodies: Worsening with memantine
Ridha, B. H., Josephs, K. A., & Rossor, M. N. (2005) · Neurology · doi:10.1212/01.wnl.0000172351.95783.8e · Cited by 93 · see citing works
Warshaw, G. A., & Bragg, E. J. (2014) · Health Affairs · doi:10.1377/hlthaff.2013.1232 · Cited by 75 · see citing works
NMDARs Mediate the Role of Monoamine Oxidase A in Pathological Aggression
Bortolato, M., Godar, S. C., Melis, M., Soggiù, A., Roncada, P., Casu, A., Flore, G., Chen, K., Frau, R., Urbani, A., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0225-12.2012 · Cited by 70 · see citing works
Memantine: efficacy and safety in mild-to-severe Alzheimer's disease
Tampi, R. R., & van Dyck, C. H. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.2007.3.2.245 · Cited by 57 · see citing works
Mičuda, S., Mundlova, L., Anzenbacherová, E., et al. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0825-1 · Cited by 56 · see citing works
Memantine: New prospective in bipolar disorder treatment
Serra, G. (2014) · World Journal of Psychiatry · doi:10.5498/wjp.v4.i4.80 · Cited by 32 · see citing works
Strzelecki, D., Tabaszewska, A., Barszcz, Z., Józefowicz, O., Kropiwnicki, P., & Rabe‐Jabłońska, J. (2013) · Psychiatry Investigation · doi:10.4306/pi.2013.10.4.421 · Cited by 29 · see citing works
Incidence and Course of Depression in Patients with Alzheimer's Disease
Ryu, S., Jung, H., Lee, K. J., et al. (2017) · Psychiatry Investigation · doi:10.4306/pi.2017.14.3.271 · Cited by 25 · see citing works
Lee, S.-Y., Wang, T., Chen, S., Chang, Y., Chen, P. S., Huang, S., Tzeng, N., Wang, L., Lee, I., Chen, K.-C., et al. (2020) · International Journal of Bipolar Disorders · doi:10.1186/s40345-019-0174-8 · Cited by 18 · see citing works
Zitnak, A. (1960) · Science · doi:10.1126/science.131.3393.66-c · Cited by 8 · see citing works
Stellenwert von MAO-B-Inhibitoren und NMDA-Antagonisten in der Therapie des Morbus Parkinson
Kassubek, J., Büttner, T., Reichmann, H., et al. (2010) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/s-0029-1245166 · Cited by 3 · see citing works
Flagged first, then by citations
Research works printed but not linked: 4
- Rosenbaum SB, Gupta V, Palacios JL. Ketamine. [Updated 2022 Jun 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470 357/
- Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012 Jan;62(1):63-77. doi: 10.1016/j.neuropharm.2011.07.036. Epub 2011 Aug 3. PMID: 21827775; PMCID: PMC3205453. · DOI · Paper page
- Peeters M, Romieu P, Maurice T, Su TP, Maloteaux JM, Hermans E. Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine. Eur J Neurosci. 2004 Apr;19(8):2212-20. doi: 10.1111/j.0953-816X.2004.03297.x. PMID: 15090047. · DOI
- Ryu SH, Jung HY, Lee KJ, Moon SW, Lee DW, Hong N, Kee BS, Kim DH, Han C, Lee CU. Incidence and course of depression in patients with Alzheimer's Disease. Psychiatry Investig. 2017 May;14(3):271-280. doi: 10.4306/pi.2017.14.3.271. Epub 2017 May 16. PMID: 28539945; PMCID: PMC5440429 · DOI
Cited by
Sorted by citations
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108 · see citing works
- Authors
- Lepkowsky, C. M.
- Affiliations
- Independent Practice, 1143 Deer Trail Lane, Solvang, CA 93463-9519
- Corresponding author
- Lepkowsky, Charles M.
- Venue
- Medical Research Archives
- Publisher
- Knowledge Enterprise Journals
- Published
- 2022-10-31
- Volume
- 10
- Issue
- 10
- Pages
- 1-12
- ISSN
- 2375-1916 (ISSN-L)
- 2375-1924
- OpenAlex
- W4312963977
- Cited by
- 2
- References
- 32
- Citations by year
- 2026: 1 · 2023: 1
- FWCI
- 0.16
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Medical Research Archives (publishedVersion)
- HAL (submittedVersion)
- Funders
- American Psychological Association
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pharmacological Receptor Mechanisms and Effects
- Keywords
- Alzheimer's disease, memantine, NMDA receptor antagonism, glutamate excitotoxicity, major depressive disorder, neurodegeneration, drug repurposing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
